STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) (STDAF) Receives Consensus Recommendation of “” from Analysts

STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) (NASDAQ:STDAF) has received a consensus broker rating score of 0.00 () from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating.

Zacks has also assigned STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) an industry rank of 93 out of 265 based on the ratings given to its competitors.

STDAF has been the subject of a number of research analyst reports. DZ Bank AG reiterated a “neutral” rating on shares of STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) in a research report on Monday, February 27th. Zacks Investment Research downgraded shares of STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 15th.

STADA ARZNEIMITTEL NP (NASDAQ:STDAF) opened at 57.93 on Wednesday. The firm has a 50-day moving average of $58.73 and a 200-day moving average of $53.19. The firm has a market cap of $3.64 billion and a price-to-earnings ratio of 27.82. STADA ARZNEIMITTEL NP has a one year low of $36.94 and a one year high of $62.20.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Mideast Time and is the sole property of of Mideast Time. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at

5 Day Chart for NASDAQ:STDAF

Get a free copy of the Zacks research report on STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) (STDAF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA ARZNEIMITTEL NPV(REGD) (VINKULIERT) and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2017 Mideast Time.